Gimoti

Evoke Pharma, Inc. (NASDAQ: EVOK) shares have lost about 51% of their value year to date compared to the 9.4%-gain in the iShares NASDAQ Biotechnology Index (NASDAQ: IBB) and a steeper 20% jump in the broader S&P 500 Index. In early March, the stock hit a long-term support around the $2.35...

Biotech stocks came under selling pressure in March, but much of the FDA decisions of the month produced positive results. PDUFA dates are deadlines for the FDA to review new drugs. The FDA is normally given 10 months to review new drugs. If a drug is selected for priority review, the FDA is...